Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.55 |
| ▸ | NOS1 | P29475 | 6/20 | 0.49 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS3 | P29474 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9678723 | 1.00 | CYP1A2 (0.55) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL4860248 | 1.00 | CYP1A2 (0.55) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7739575 | 0.98 | CYP1A2 (0.59) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7741618 | 0.98 | CYP1A2 (0.59) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7733050 | 0.98 | CYP1A2 (0.59) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7741474 | 0.95 | CYP1A2 (0.53) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL918157 | 0.94 | CYP1A2 (0.52) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL4864166 | 0.94 | CYP1A2 (0.52) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL6516575 | 0.94 | CYP1A2 (0.52) | CYP1A2NOS1NOS2NOS3ALDH1A1 | |
| SCHEMBL7739414 | 0.93 | CYP1A2 (0.52) | CYP1A2NOS1NOS2NOS3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119752742-A | Pre-harvest physiological management method for improving color and smell quality of spirulina | 中国海洋大学 | 2025-04-04 | — | — | CN | disclosed |
| US-20230331673-A1 | COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE | CRESCENTA BIOSCIENCES (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | disclosed |
| US-7727979-B2 | Guanidine derivatives and their use as neuropeptide FF receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-01 | — | — | US | disclosed |
| US-20080125310-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-05-29 | — | — | US | disclosed |
| US-7323604-B2 | Hydride reduction of α,β-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-01-29 | — | — | US | disclosed |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-31 | — | — | US | disclosed |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-07-20 | — | — | US | disclosed |
| US-6410748-B1 | Alicycli c group-containing monomer | KABUSHIKI KAISHA TOSHIBA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-6291129-B1 | LIGHT SENSITIVE ELEMENT WITH UNSATURATED POLYMERS | KABUSHIKI KAISHA TOSHIBA (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | CYP1A2 3773/4885NOS1 4611/4885NOS2 4790/4885 |
| US-20060194788-A1 | Guanidine derivatives and their use as neuropeptide ff receptor antagonists | NPFFR1, OGFR, NPFFR2 | CYP1A2 4367/4885NOS1 2228/4885NOS2 2017/4885 |
| US-20230331673-A1 | COMPOSITION OF COMPOUNDS THAT MODULATE CELL METABOLISM AND METHODS OF USE | FABP4, FABP1, FABP3 | CYP1A2 2551/4885NOS1 3839/4885NOS2 4512/4885 |
| US-20060161024-A1 | Hydride reduction of alpha, beta-unsaturated carbonyl compounds using chiral organic catalysts | ECH1, CBR1, DHCR24 | CYP1A2 424/4885NOS1 559/4885NOS2 832/4885 |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | CYP1A2 3272/4885NOS1 4340/4885NOS2 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.